Company & Sponsor Intelligence

The Alfred

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting0

Completed3

Countries1

Therapeutic footprint

depressionschizophrenia

Indexed studies

NCT00168311A Double-Blind Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Negative Symptoms in Schizophrenia
schizophrenia · AustraliaNA

NCT00168272Priming rTMS In Major Depression
depression · AustraliaNA

NCT00361543Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia
schizophrenia · AustraliaPHASE4

Intelligence layer updated: 2026-10-20 06:14:04.499488+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →